In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Glaxo, NeuroSearch end deal to co-develop antidepressant

Executive Summary

Glaxo Wellcome and Danish biotech NeuroSearch will co-develop the latter's Phase II antidepressant NS2389. Glaxo paid (uf)$10mm up front and could pay up to $47mm more in milestones, plus sales royalties. It gets exclusive rights except in Nordic and Baltic countries.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register